Literature DB >> 34249444

Predicting early recurrence for resected pancreatic ductal adenocarcinoma: a multicenter retrospective study in China.

Weikang Liu1, Bingjun Tang1, Feng Wang2, Chang Qu1, Hao Hu1,3, Yan Zhuang1, Hongqiao Gao1, Xuehai Xie1, Xiaodong Tian1, Yinmo Yang1.   

Abstract

A precise classification of early recurrence (ER) after radical surgery of pancreatic ductal adenocarcinoma (PDAC) has not been standardized. We aim to develop an optimal cut-off based on scientific evidence to distinguish early and late recurrence (LR) for PDAC after radical surgery and develop a predictive model for ER of PDAC. The best threshold for recurrence-free survival (RFS) was assessed with a minimum P-value method, and patients were categorized into ER and LR groups. We used a logistic regression model to assess potential risk factors for ER and develop a predictive model for ER risk. The best threshold between high-risk and intermediate-high-risk groups was identified by using the receiver operating characteristic curve. Among 3,279 patients included, 1,234 (37.6%) experienced ER. The RFS of 9 months is the optimal threshold to distinguish ER and LR. Univariable and multivariable analysis identified four preoperative risk factors for ER, including larger tumor maximal diameter on computed tomography (CT), enlarged lymph nodes on CT, carbohydrate antigen (CA) 125 > 35 U/ml, and CA19-9 > 235 U/ml. The concordance index (C-index) for the predictive model in the training cohort and the validation cohort was 0.651 (95% confidence interval (CI): 0.624-0.678), and 0.636 (95% CI: 0.593-0.679), respectively, showing promising predictive ability. The high-risk group had a score above 203, and the corresponding risk of ER for this group was 56.7%. An RFS of 9 months is the best threshold to distinguish ER and LR. The model can accurately predict the risk of ER in PDAC after radical resection, and risk grouping can predict the patients who could benefit from upfront surgery. AJCR
Copyright © 2021.

Entities:  

Keywords:  Early recurrence; pancreatic ductal adenocarcinoma; predictive model

Year:  2021        PMID: 34249444      PMCID: PMC8263647     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  28 in total

1.  Comparative Accuracy of Tumor Size Assessment and Stage Analysis by Imaging Modalities Versus Gross Examination for Pancreatic Ductal Adenocarcinoma.

Authors:  Ari Kassardjian; Nicholas Stanzione; Hanlin L Wang
Journal:  Pancreas       Date:  2019-02       Impact factor: 3.327

2.  Pancreatic adenocarcinoma: variability in measurements of tumor size among computed tomography, magnetic resonance imaging, and pathologic specimens.

Authors:  Chao Ma; Panpan Yang; Jing Li; Yun Bian; Li Wang; Jianping Lu
Journal:  Abdom Radiol (NY)       Date:  2020-03

3.  Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.

Authors:  Ippei Matsumoto; Yoshiaki Murakami; Makoto Shinzeki; Sadaki Asari; Tadahiro Goto; Masaji Tani; Fuyuhiko Motoi; Kenichiro Uemura; Masayuki Sho; Sohei Satoi; Goro Honda; Hiroki Yamaue; Michiaki Unno; Takahiro Akahori; A-Hon Kwon; Masanao Kurata; Tetsuo Ajiki; Takumi Fukumoto; Yonson Ku
Journal:  Pancreatology       Date:  2015-10-03       Impact factor: 3.996

4.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

5.  Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.

Authors:  Armin Rump; Yoshihiro Morikawa; Minoru Tanaka; Sawako Minami; Naohiko Umesaki; Masaki Takeuchi; Atsushi Miyajima
Journal:  J Biol Chem       Date:  2003-12-15       Impact factor: 5.157

6.  Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma.

Authors:  Brian A Boone; Herbert J Zeh; Brady K Mock; Paul J Johnson; Igor Dvorchik; Ken Lee; A James Moser; David L Bartlett; J Wallis Marsh
Journal:  HPB (Oxford)       Date:  2013-04-22       Impact factor: 3.647

7.  A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma.

Authors:  Shinichi Ikuta; Takashi Sonoda; Tsukasa Aihara; Naoki Yamanaka
Journal:  Ann Transl Med       Date:  2019-09

8.  CA19-9 for detecting recurrence of pancreatic cancer.

Authors:  Azadeh Azizian; Felix Rühlmann; Tanja Krause; Markus Bernhardt; Peter Jo; Alexander König; Mathias Kleiß; Andreas Leha; Michael Ghadimi; Jochen Gaedcke
Journal:  Sci Rep       Date:  2020-01-28       Impact factor: 4.379

9.  The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy.

Authors:  Hironobu Suto; Keiichi Okano; Minoru Oshima; Yasuhisa Ando; Shigeo Takahashi; Toru Shibata; Hideki Kamada; Hideki Kobara; Tsutomu Masaki; Yasuyuki Suzuki
Journal:  BMC Surg       Date:  2019-12-03       Impact factor: 2.102

10.  Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma.

Authors:  Li Wang; Ping Dong; Weiguo Wang; Mao Li; Weiming Hu; Xubao Liu; Bole Tian
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

View more
  1 in total

1.  The management strategy of pancreatic cancer in the era of systemic therapy-"Surgery First" or "Surgery Last"?

Authors:  Yinmo Yang; Xiaodong Tian
Journal:  Hepatobiliary Surg Nutr       Date:  2022-08       Impact factor: 8.265

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.